Literature DB >> 23295747

Enhanced T cell activation in Plasmodium falciparum malaria-infected human immunodeficiency virus-1 patients from Mozambique.

Helena Chavale1, Joanna Reis Santos-Oliveira, Alda Maria Da-Cruz, Sonia Enosse.   

Abstract

Human immunodeficiency virus (HIV)-1 infection has an important impact on malaria. Plasmodium falciparum and HIV-1 co-infected patients (Pf/HIV) present with a high degree of anaemia, enhanced parasitaemia and decreased CD4⁺ T cell counts, which increase the risk of developing severe malaria. In addition, infection with either Pf or HIV-1 alone causes extensive immune activation. Our hypothesis was that lymphocyte activation is potentiated in Pf/HIV co-infected patients, consequently worsening their immunosuppressed state. To test this hypothesis, 22 Pf/HIV patients, 34 malaria patients, 29 HIV/AIDS patients and 10 healthy controls without malaria or HIV/acquired immune deficiency syndrome (AIDS) from Maputo/Mozambique were recruited for this study. As expected, anaemia was most prevalent in the Pf/HIV group. A significant variation in parasite density was observed in the Pf/HIV co-infected group (110-75,000 parasites/µL), although the median values were similar to those of the malaria only patients. The CD4⁺ T cell counts were significantly lower in the Pf/HIV group than in the HIV/AIDS only or malaria only patients. Lymphocyte activation was evaluated by the percentage of activation-associated molecules [CD38 expression on CD8⁺ and human leukocyte antigen-DR expression on CD3⁺ T cells]. The highest CD38 expression was detected in the Pf/HIV co-infected patients (median = 78.2%). The malaria only (median = 50%) and HIV/AIDS only (median = 52%) patients also exhibited elevated levels of these molecules, although the values were lower than those of the Pf/HIV co-infected cases. Our findings suggest that enhanced T-cell activation in co-infected patients can worsen the immune response to both diseases.

Entities:  

Mesh:

Year:  2012        PMID: 23295747     DOI: 10.1590/s0074-02762012000800004

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  6 in total

1.  Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria.

Authors:  Feyisayo Ebenezer Jegede; Tinuade Ibijoke Oyeyi; Surajudeen Abiola Abdulrahman; Henry Akwen Mbah; Titilope Badru; Chinedu Agbakwuru; Oluwasanmi Adedokun
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

2.  An Assessment of Malaria Parasite Density among HIV/AIDS-Subjects at Different Levels of CD4 T-Cells Prior to Antimalarial Therapy at Chulaimbo Sub-County Hospital, Western Kenya.

Authors:  J K Kirinyet
Journal:  J Trop Med       Date:  2019-07-01

3.  Should we care about Plasmodium vivax and HIV co-infection? A systematic review and a cases series from the Brazilian Amazon.

Authors:  Paola López Del-Tejo; Nadia Cubas-Vega; Cecilia Caraballo-Guerra; Bernardo Maia da Silva; Jefferson da Silva Valente; Vanderson Souza Sampaio; Djane Clarys Baia-da-Silva; Daniel Barros Castro; Flor Ernestina Martinez-Espinosa; André Machado Siqueira; Marcus Vinícius Guimarães Lacerda; Wuelton Marcelo Monteiro; Fernando Val
Journal:  Malar J       Date:  2021-01-06       Impact factor: 2.979

Review 4.  Interactions between malaria and human immunodeficiency virus anno 2014.

Authors:  J-P Van Geertruyden
Journal:  Clin Microbiol Infect       Date:  2014-04       Impact factor: 8.067

5.  SIV infection aggravates malaria in a Chinese rhesus monkey coinfection model.

Authors:  Guangjie Liu; Youjia Li; Li Qin; Yongxiang Yan; Yijian Ye; Yue Chen; Cuizhu Huang; Siting Zhao; Yongchao Yao; Zhong Su; Xiaoping Chen
Journal:  BMC Infect Dis       Date:  2019-11-12       Impact factor: 3.090

6.  Increased malaria parasitaemia among adults living with HIV who have discontinued cotrimoxazole prophylaxis in Kitgum district, Uganda.

Authors:  Philip Orishaba; Joan N Kalyango; Pauline Byakika-Kibwika; Emmanuel Arinaitwe; Bonnie Wandera; Thomas Katairo; Wani Muzeyi; Hildah Tendo Nansikombi; Alice Nakato; Tobius Mutabazi; Moses R Kamya; Grant Dorsey; Joaniter I Nankabirwa
Journal:  PLoS One       Date:  2020-11-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.